As expected, compared to the current scenario of tissue testing only, the study showed that implementing EGFR mutation plasma testing overall would enable more lung cancer patients in Greece to undergo molecular diagnostic testing to guide therapy decisions, including patients with comorbid medical conditions or who are in extremis that preclude tissue biopsy. Here, EGFR is linked to lung carcinoma.